These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6987253)

  • 1. Time-action characteristics of regular and NPH insulin in insulin-treated diabetics.
    Roy B; Chou MC; Field JB
    J Clin Endocrinol Metab; 1980 Mar; 50(3):475-9. PubMed ID: 6987253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged action of regular insulin in diabetic patients: lack of relationship to circulating insulin antibodies.
    Gardner DF; Wilson HK; Podet EJ; Arakaki RF; Nell LJ; Thomas JW; Crane MM; Field JB
    J Clin Endocrinol Metab; 1986 Apr; 62(4):621-7. PubMed ID: 3512590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical use of NPH insulin (author's transl)].
    Roesner M; Sauer H
    Dtsch Med Wochenschr; 1976 Jun; 101(23):886-9. PubMed ID: 1269430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human (recombinant DNA) and porcine NPH insulins are unequally effective in diabetic patients. A comparative study using continuous blood glucose monitoring.
    Richard JL; Rodier M; Cavalié G; Mirouze J; Monnier L
    Acta Diabetol Lat; 1984; 21(3):211-7. PubMed ID: 6393670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption kinetics of regular and isophane (NPH) insulin in the normal dog.
    Goeders LA; Esposito LA; Peterson ME
    Domest Anim Endocrinol; 1987 Jan; 4(1):43-50. PubMed ID: 3333933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Action profile of a semisynthetic human isophane zinc insulin compared with customary isophane insulin].
    Gin H; Delafaye C; Morlat P; Aubertin J
    Diabete Metab; 1992; 18(6):445-50. PubMed ID: 1297601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of subcutaneous regular insulin in type I diabetic patients: assessment using a glucose clamp technique.
    Gardner DF; Arakaki RF; Podet EJ; Nell LJ; Thomas JW; Field JB
    J Clin Endocrinol Metab; 1986 Sep; 63(3):689-94. PubMed ID: 3525600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate-acting insulin preparations: NPH and lente.
    Deckert T
    Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
    Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitional NPH insulin therapy for critically ill patients receiving continuous enteral nutrition and intravenous regular human insulin.
    Dickerson RN; Wilson VC; Maish GO; Croce MA; Minard G; Brown RO
    JPEN J Parenter Enteral Nutr; 2013 Jul; 37(4):506-16. PubMed ID: 22914894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal activity profiles of NPH and [Nepsilon-palmitoyl Lys (B29)] human insulins in subjects with IDDM.
    Radziuk J; Pye S; Bradley B; Braaten J; Vignati L; Roach P; Bowsher R; DiMarchi R; Chance R
    Diabetologia; 1998 Jan; 41(1):116-20. PubMed ID: 9498640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, effectiveness and side effects of highly purified porcine NPH-insulin preparations (Leo).
    Kølendorf K; Aaby P; Westergaard S; Deckert T
    Eur J Clin Pharmacol; 1978 Nov; 14(2):117-24. PubMed ID: 363432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Search for the most practical regular/NPH mixtures for type I diabetic patients.
    Renner R; Vocke K; Hepp KD
    Diabetes Care; 1982; 5 Suppl 2():53-6. PubMed ID: 6765541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the activity profiles of two fixed combinations of regular/NPH human insulin (recombinant DNA) of different compositions with a fixed regular/NPH porcine insulin combination (PPI) in insulin-dependent diabetic individuals.
    Sailer D; Ludwig T; Kolb S
    Diabetes Care; 1982; 5 Suppl 2():57-9. PubMed ID: 6765542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling.
    Woodworth JR; Howey DC; Bowsher RR
    Diabetes Care; 1994 Jan; 17(1):64-9. PubMed ID: 8112192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of porcine and human isophane (NPH) insulins in normal subjects.
    Owens DR; Jones IR; Birtwell AJ; Burge CT; Luzio S; Davies CJ; Heyburn P; Heding LG
    Diabetologia; 1984 Apr; 26(4):261-5. PubMed ID: 6376233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin glargine (Lantus).
    Owens DR; Griffiths S
    Int J Clin Pract; 2002; 56(6):460-6. PubMed ID: 12166545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical observation on brittle diabetes.
    Lev-Ran A
    Arch Intern Med; 1978 Mar; 138(3):372-6. PubMed ID: 629631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of a 40 IU/ml porcine lente insulin preparation in diabetic cats: findings during the first week and after 5 or 9 weeks of therapy.
    Martin GJ; Rand JS
    J Feline Med Surg; 2001 Mar; 3(1):23-30. PubMed ID: 11716627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.